semaglutide bmi 25 Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial Semaglutide cuts BMI by 19%

Injection-site reactions are possible with any subcutaneous peptide

A prominent drug effect that contributes to drunk driving is psychomotor impairment, in which mental efforts and reflexes are slowed

Dosage protocols and reconstitution Proper dosing is critical for both efficacy and tolerability

The ranges below are approximate, pooled from clinical trials

Liposomal formulations, PEG-PLGA nanoparticles, and dendrimer or polymer micelles have each prolonged plasma half-life and shielded riboflavin from rapid renal loss, while surface ligandssuch as wheat-germ agglutinin, transferrin-mimic peptides, and BBB-shuttling sequencesenable active transcytosis across the bloodbrain barrier (8689)

doi: 10.1111/j.1476-5381.2009.00492.x 179